Dacosta v. NOVARTIS AG, NOVARTIS PHARMACEUTICALS CORP.

242 F. Supp. 2d 765, 2002 U.S. Dist. LEXIS 25530, 2002 WL 31973837
CourtDistrict Court, D. Oregon
DecidedJune 18, 2002
DocketCV 01-800-BR
StatusPublished
Cited by1 cases

This text of 242 F. Supp. 2d 765 (Dacosta v. NOVARTIS AG, NOVARTIS PHARMACEUTICALS CORP.) is published on Counsel Stack Legal Research, covering District Court, D. Oregon primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Dacosta v. NOVARTIS AG, NOVARTIS PHARMACEUTICALS CORP., 242 F. Supp. 2d 765, 2002 U.S. Dist. LEXIS 25530, 2002 WL 31973837 (D. Or. 2002).

Opinion

OPINION AND ORDER

BROWN, District Judge.

Plaintiffs originally filed a Complaint in state court that alleged Plaintiff Rosemary DaCosta suffered severe heart injuries due to Defendants’ failure to warn Plaintiffs’ physician about certain health risks associated with pharmaceutical products allegedly researched, developed, manufactured, marketed, distributed, and sold by Defendant Novartis Pharmaceuticals Corporation (NPC) and its Swiss parent company, Defendant Novartis AG (NAG). NPC timely removed the action to this Court pursuant to 28 U.S.C. § 1441 on the basis of diversity jurisdiction. 1

NAG is represented in this matter by local counsel and the national law firm of Mayer, Brown, Rowe & Maw. On February 5, 2002, the Court granted the applications for special admission pro hac vice of three attorneys from that firm, Dennis P. Orr, Grant J. Esposito, and Elizabeth L. Goldsmith. On April 26, 2002, the Court suspended those special admissions until further notice because of alleged discovery abuses by counsel. The Court, however, granted counsel leave to file motions for readmission.

This matter now comes before the Court on NAG’s Motion for Readmission Pro Hac Vice (# 136) of Orr, Esposito, and Goldsmith. For the following reasons, the Court GRANTS the Motion for Readmission and VACATES the Court’s Order that suspended until further notice the special admissions pro hac vice of Orr, Esposito, and Goldsmith.

PROCEDURAL BACKGROUND

The events that precipitated the Court’s suspension of counsels’ special admissions can be traced to the initial stages of this litigation. From the outset, NAG consistently has taken the position that it is not subject to the personal jurisdiction of this Court and has contested its obligation to submit to Plaintiffs’ discovery demands on various fronts.

Within a month of NPC’s removal of this action, NAG filed an initial Motion to Dismiss Plaintiffs’ Complaint for lack of personal jurisdiction. On July 10, 2001, the Court denied NAG’s Motion to Dismiss for failure to comply with the certification requirement of LR 7.1(a). 2 The Court, however, gave NAG leave to renew the motion to dismiss following the Court’s decision on Plaintiffs’ then-pending Motion to Remand.

On September 18, 2001, NAG filed a Renewed Motion to Dismiss for Lack of Personal Jurisdiction. In response to that Motion, Plaintiffs filed a Motion to Stay Determination of NAG’s Renewed Motion to Dismiss pending a period of jurisdictional discovery. On October 10, 2001, the Court denied NAG’s Renewed Motion to Dismiss, granted Plaintiffs the right to *767 conduct jurisdictional discovery, and permitted NAG to refile its Motion to Dismiss after Plaintiffs completed jurisdictional discovery. The Court ordered the parties to complete jurisdictional discovery by January 4, 2002, and also set a January 25, 2002, deadline for NAG to file a renewed motion to dismiss.

Pursuant to this order, Plaintiffs attempted to serve various requests for production and a notice of organizational deposition. NAG refused to comply with Plaintiffs’ discovery requests and asserted Plaintiffs had to use the discovery procedures established by the Hague Convention on the Taking of Evidence Abroad in Civil or Commercial Matters (Hague Evidence Convention) rather than the Federal Rules of Civil Procedure because NAG is a Swiss company without any office or base in the United States. On November 11, 2001, Plaintiffs filed a Motion for Leave to Conduct Jurisdictional Discovery Pursuant to the Federal Rules rather than the Hague Evidence Convention.

On November 27, 2001, the Court heard oral argument on Plaintiffs’ discovery motion. The Court granted in part and denied in part Plaintiffs’ Motion for Leave to Conduct Jurisdictional Discovery Pursuant to the Federal Rules. In particular, the Court stated:

I am ordering that judicially supervised, narrowly tailored jurisdictional discovery against Novartis AG proceed pursuant to the Federal Rules of Civil Procedure.
That conclusion assumes that the discovery, which will go forward under the Federal Rules, is, in fact, specifically tailored to address the question of jurisdiction and no more, and it assumes, therefore, that the Plaintiff will, as I indicated earlier, review each of the now outstanding discovery requests with that standard in mind, and issue a definitive statement to the Defendant specifying which requests Plaintiff contends are, in fact, narrowly tailored and specifically focused towards the jurisdictional inquiry.

The Court ordered Plaintiffs to supplement or to clarify their discovery requests by December 3, 2001. The Court further ordered NAG to serve objections to those requests “that articulate specifically the bases why the Defendant contends the request is not reasonably tailored to lead to the discovery of evidence pertinent to the jurisdictional inquiry” by December 10, 2001. The Court also waived any requirement that Plaintiffs file a formal, written motion to compel responses to these requests and scheduled a hearing on NAG’s objections for December 14, 2001. Finally, the Court extended the jurisdictional discovery period until April 5, 2002.

On December 10, 2001, NAG filed its Responses and Objections to Plaintiffs’ Amended Request for Production of Documents and to Plaintiffs’ Amended Notice of Organizational Deposition. NAG did not articulate specific objections to each request for production as ordered by the Court. Instead, NAG posed sixteen separate “General Responses and Objections” to Plaintiffs’ Requests, several of which contained multiple subparts. In a single General Objection, NAG objected to all of Plaintiffs’ requests on the grounds that the requests were vague, redundant, burdensome, overbroad, oppressive, not reasonably particular, not narrowly tailored as required by the Court in this case, not susceptible to a reasoned interpretation, and sought information that was not reasonably calculated to lead to the discovery of admissible evidence. NAG’s 15 other General Objections addressed additional alleged problems with Plaintiffs’ requests, including the impracticality of NAG reviewing “all of the materials in its possession, custody or control to determine if any information contained anywhere in their *768 files may be responsive to any of the requests contained in [Plaintiffs’] Request.” In response to the particular requests at issue, NAG objected as follows:

REQUEST FOR PRODUCTION NO. 1: Any express agreement by which NAG has consented that NPC can, will, or has the power to act on NAG’s behalf and subject to NAG’s control for any purpose.
RESPONSE: Subject to the foregoing objections, NAG will produce non-privileged documents it reasonably understands to be responsive to this request, if any.
%

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Holley v. Gilead Sciences, Inc.
N.D. California, 2020

Cite This Page — Counsel Stack

Bluebook (online)
242 F. Supp. 2d 765, 2002 U.S. Dist. LEXIS 25530, 2002 WL 31973837, Counsel Stack Legal Research, https://law.counselstack.com/opinion/dacosta-v-novartis-ag-novartis-pharmaceuticals-corp-ord-2002.